tiprankstipranks
Trending News
More News >
Advertisement

ISRA - ETF AI Analysis

Compare

Top Page

ISRA

VanEck Israel ETF (ISRA)

Rating:69Neutral
Price Target:
ISRA, the VanEck Israel ETF, earns a solid overall rating driven largely by strong Israeli banks like Bank Leumi, Poalim, and Mizrahi Tefahot, which show healthy financial performance, supportive technical trends, and generally attractive valuations. Additional support comes from financially strong names like Check Point, Elbit Systems, Phoenix, and Tower Semiconductor, though some face valuation or technical headwinds. Weaker contributors such as CyberArk, with profitability and technical challenges, and Teva, which is still working through financial and debt issues, slightly hold back the fund, and investors should note the key risk that the ETF is heavily concentrated in a single country and a few major financial and tech names.
Positive Factors
Solid Recent Performance
The ETF has shown strong gains over the past three months and a positive trend year to date, indicating recent momentum.
Concentrated Exposure to Leading Israeli Companies
Many of the top holdings, especially major banks and defense-related firms, have delivered steady to strong performance, helping support the fund’s returns.
Diversified Across Key Sectors
Holdings spread across financials, technology, health care, and several smaller sectors help reduce the impact of weakness in any single industry.
Negative Factors
High Expense Ratio
The fund’s relatively high fee means more of the investment return goes to costs instead of staying in investors’ pockets.
Heavy Concentration in Financials and Technology
A large share of assets in just two sectors increases the risk that a downturn in financial or tech stocks could hurt overall performance.
Regional and Geopolitical Focus
The ETF’s strong tilt toward Israel, even with some U.S. exposure, makes it sensitive to regional economic and geopolitical developments.

ISRA vs. SPDR S&P 500 ETF (SPY)

ISRA Summary

The VanEck Israel ETF (ISRA) tracks the BlueStar Israel Global Index and gives you broad exposure to Israeli companies, including both local firms and Israel-linked businesses listed in the U.S. It holds a mix of financial, technology, and health care stocks, with well-known names like Teva Pharmaceutical and CyberArk Software. Someone might invest in ISRA to tap into Israel’s reputation as a “Start-Up Nation” and add international diversification to their portfolio. A key risk is that it is concentrated in one country, so its value can rise or fall sharply with economic or political events in Israel.
How much will it cost me?The VanEck Israel ETF (ISRA) has an expense ratio of 0.59%, which means you’ll pay $5.90 per year for every $1,000 invested. This is slightly higher than average because the fund is focused on a specific niche market (Israeli securities) and requires more active management compared to broad, passively managed index funds.
What would affect this ETF?The VanEck Israel ETF (ISRA) could benefit from Israel's strong reputation in technology and innovation, particularly in cybersecurity, biotechnology, and clean energy, which are key drivers of growth. However, potential risks include geopolitical tensions in the Middle East and global economic slowdowns, which could negatively impact the financial and industrial sectors that make up a significant portion of the ETF's holdings.

ISRA Top 10 Holdings

ISRA is leaning heavily on Israel’s big banks and a few standout innovators to drive returns. Leumi, Poalim, and other financial names are steadily climbing and form the backbone of the fund, giving it a solid, income-friendly core. On the growth side, Elbit Systems and Tower Semiconductor have been rising sharply, adding some rocket fuel. Teva is recovering but still feels like a work-in-progress, while cyber leaders like CyberArk and Check Point have been more mixed, occasionally putting a lid on performance. Overall, it’s a concentrated bet on Israel’s homegrown financial and tech strength.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Teva Pharmaceutical10.33%$13.83M$37.48B92.22%
63
Neutral
Leumi8.50%$11.39M₪110.71B96.92%
80
Outperform
Poalim7.34%$9.83M₪100.95B78.62%
79
Outperform
Elbit Systems5.64%$7.56M₪102.11B129.94%
73
Outperform
CyberArk Software5.48%$7.34M$21.75B16.13%
52
Neutral
Check Point3.95%$5.29M$19.27B-17.66%
76
Outperform
Discount3.22%$4.31M₪44.83B60.75%
75
Outperform
Mizrahi Tefahot3.12%$4.18M₪63.27B127.80%
80
Outperform
Phoenix2.75%$3.69M₪38.25B166.91%
79
Outperform
Tower2.68%$3.59M₪46.53B175.58%
76
Outperform

ISRA Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
59.51
Positive
100DMA
56.61
Positive
200DMA
52.37
Positive
Market Momentum
MACD
1.11
Positive
RSI
58.25
Neutral
STOCH
61.93
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ISRA, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 62.56, equal to the 50-day MA of 59.51, and equal to the 200-day MA of 52.37, indicating a bullish trend. The MACD of 1.11 indicates Positive momentum. The RSI at 58.25 is Neutral, neither overbought nor oversold. The STOCH value of 61.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ISRA.

ISRA Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$134.07M0.59%
$997.84M0.24%
$980.41M0.09%
$933.41M0.85%
$929.29M0.50%
$770.47M0.59%
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ISRA
VanEck Israel ETF
62.87
18.57
41.92%
DFSI
Dimensional International Sustainability Core 1 ETF
FLGB
Franklin FTSE United Kingdom ETF
WCMI
First Trust WCM International Equity ETF
SEIE
SEI Select International Equity ETF
EIS
iShares MSCI Israel ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement